MyFinsight
Home
Blog
About
Contact
Download
Download image
Issuance of preferred
stock-Series CPreferred...
$151,000K
Issuance of preferred
stock-Series BPreferred...
$8,433K
Exercise of stock options
$156K
Net cash provided by
financing activities
$159,142K
Canceled cashflow
$447K
Net increase
(decrease) in cash and cash...
-$31,318K
Canceled cashflow
$159,142K
Maturities of marketable
securities
$25,018K
Accrued expenses
$4,510K
Non-cash research and
development services
$1,999K
Stock-based compensation
$1,440K
Other
-$43K
Preferred stock issuance
costs
$447K
Net cash used in
investing activities
-$118,858K
Canceled cashflow
$25,018K
Net cash used in
operating activities
-$71,602K
Canceled cashflow
$7,992K
Purchases of marketable
securities
$143,852K
Purchase of property,
plant and equipment
$24K
Net loss
-$69,995K
Prepaid expenses and
other current assets
$8,235K
Accrued interest earned
$647K
Net accretion of
discount/premium on debt...
$556K
Accounts payable
-$122K
Other current
liabilities and lease...
-$39K
Back
Back
Cash Flow
source: myfinsight.com
Veradermics, Inc (MANE)
Veradermics, Inc (MANE)